Exo acquires Medo AI to improve ultrasound imaging

[Image from Exo]Exo announced today that it will acquire artificial intelligence (AI) developer Medo to make ultrasound imaging faster and simpler.

Redwood City, California-based Exo intends to integrate Medo’s proprietary Sweep AI technology into its ultrasound platform to make the imaging modality more accessible to a wider range of caregivers.

No financial terms for the acquisition were disclosed.

According to a news release, Canada-based Medo’s ultrasound AI technology radically lowers the expertise required to diagnose common and critical conditions through automated image acquisition and interpretation, giving non-experts the ability to conduct high-quality exams quickly and accurately.

The company brings with it two FDA-cleared AI algorithms, as well as more in development, plus access to an extensive library of millions of ultrasound images and longitudinal health data to speed up point-of-care ultrasound adoption across the healt…

Read more
  • 0

Exo unveils cloud-based, point-of-care ultrasound offering

[Image from Exo]Exo announced today that it unveiled its Exo Works point-of-care ultrasound workflow solution.

Redwood City, California-based Exo designed Exo Works to enable physicians to easily document, review, bill and manage quality assurance all from one platform within seconds.

According to a news release, Exo aims for its Exo Works platform to make it easier to manage ultrasound exams for compliance, quality assurance, credentialing and education. Its secure, cloud-based platform can be accessed by phone, tablet or web browser and it integrates with virtually any point-of-care ultrasound device and the most common EMR and hospital PACS systems.

The company designed Exo Works’ mobile-first software to reduce the time and costs associated with accurately and securely documenting patient data while providing additional tools for real-time collaboration, credentialling and tracking key program metrics for departments and individuals.

While …

Read more
  • 0

GSK-backed venture fund APVC sees opportunities in ultrasound

Juan-Pablo Mas of APVC details the firm’s investment in EXO.

Action Potential Venture Capital, a corporate investment arm of GSK, sees therapeutic opportunities in ultrasound, according to a partner at the group.

In this week’s DeviceTalks Weekly Podcast, Action Venture partner Juan-Pablo Mas explains why APCV led the recent round in Exo, a maker of the first piezoelectric micromachined ultrasonic transducer (PMUT) portable ultrasound imaging technology.

Mas also updates listeners on the venture fund’s interest in exploring other types of technologies. And he introduces LatinxVc, a non-profit group he co-founded to create opportunities for newcomers to venture capital.

Trust Securities Managing Director Kaila Krum says Medtronic (NYSE:MDT) executives are retooling the company to keep pace with smaller, more focused competitors.

Breaking down the company’s Q1 analyst ca…

Read more
  • 0